Stock IKT INHIBIKASE THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Inhibikase Therapeutics, Inc.

Equities

IKT

US45719W2052

Delayed Nasdaq
Other stock markets
 15:20:26 01/07/2024 BST 		5-day change 1st Jan Change
1.26 USD +4.13% Intraday chart for Inhibikase Therapeutics, Inc. -5.26% -0.79%
06-17 Inhibikase Therapeutics Completes Enrollment of the Phase 2 ?201? Trial Evaluating Risvodetinib in Untreated Parkinson?s Disease CI
06-05 Inhibikase Therapeutics, Inc. Announces Expansion to Its Therapeutic Pipeline CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Inhibikase Therapeutics Completes Enrollment of the Phase 2 201 Trial Evaluating Risvodetinib in Untreated Parkinson s disease
AQ
Inhibikase Therapeutics Completes Enrollment of the Phase 2 ‘201’ Trial Evaluating Risvodetinib in Untreated Parkinson’s Disease
GL
Inhibikase Therapeutics Completes Enrollment of the Phase 2 ?201? Trial Evaluating Risvodetinib in Untreated Parkinson?s Disease
CI
Inhibikase Therapeutics Announces Expansion to its Therapeutic Pipeline and Updates its Research and Development Programs
GL
Inhibikase Therapeutics, Inc. Announces Expansion to Its Therapeutic Pipeline
CI
HC Wainwright Adjusts Inhibikase Therapeutics Price Target to $23 From $27, Maintains Buy Rating
MT
Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $4.0 Million
GL
Inhibikase Therapeutics, Inc. announced that it expects to receive $7.999999 million in funding
CI
Transcript : Inhibikase Therapeutics, Inc., Q1 2024 Earnings Call, May 16, 2024
Inhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period Activity
GL
Inhibikase Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Inhibikase Therapeutics Announces Request for Withdrawal of S-1 Registration Statement
GL
Inhibikase Therapeutics Announces Final Pre-IND Meeting Outcomes for IkT-001Pro as a Treatment for Pulmonary Arterial Hypertension
GL
Inhibikase Therapeutics Announces Final Pre-Ind Meeting Outcomes for Ikt-001Pro as A Treatment for Pulmonary Arterial Hypertension
CI
Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs
GL
Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension
GL
Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension
CI
Transcript : Inhibikase Therapeutics, Inc., 2023 Earnings Call, Mar 28, 2024
Earnings Flash (IKT) INHIBIKASE THERAPEUTICS Posts 2023 Revenue $260,501
MT
Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activity
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. IKT Stock
  4. News Inhibikase Therapeutics, Inc.